Qiagen N.V. (NYSE:QGEN) Given Average Recommendation of “Hold” by Analysts

Shares of Qiagen N.V. (NYSE:QGEN) have received an average rating of “Hold” from the twelve ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $44.9789.

QGEN has been the subject of several recent research reports. Zacks Research upgraded Qiagen from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 29th. TD Cowen restated a “hold” rating and issued a $40.00 price objective (down from $46.00) on shares of Qiagen in a report on Thursday, May 7th. Stifel Nicolaus set a $36.00 price objective on Qiagen and gave the company a “hold” rating in a report on Monday, May 18th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $43.00 price objective on shares of Qiagen in a report on Thursday, April 30th. Finally, Wall Street Zen downgraded shares of Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, March 28th.

Qiagen Stock Down 1.5%

Shares of QGEN opened at $36.66 on Thursday. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49. The firm has a fifty day moving average price of $36.83 and a 200-day moving average price of $43.70. The firm has a market capitalization of $7.55 billion, a P/E ratio of 19.14, a P/E/G ratio of 3.70 and a beta of 0.66. Qiagen has a 12-month low of $32.53 and a 12-month high of $57.81.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.54 earnings per share for the quarter, meeting the consensus estimate of $0.54. The firm had revenue of $492.32 million during the quarter, compared to the consensus estimate of $496.15 million. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.During the same period in the previous year, the company posted $0.56 earnings per share. Equities research analysts expect that Qiagen will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The company also recently announced an annual dividend, which will be paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th will be issued a $0.35 dividend. This is a boost from Qiagen’s previous annual dividend of $0.26. This represents a yield of 104.0%. The ex-dividend date is Tuesday, July 7th. Qiagen’s dividend payout ratio is presently 13.61%.

Hedge Funds Weigh In On Qiagen

A number of large investors have recently added to or reduced their stakes in the company. Allworth Financial LP raised its holdings in Qiagen by 23.2% in the third quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock worth $61,000 after purchasing an additional 256 shares in the last quarter. Banque Cantonale Vaudoise raised its holdings in Qiagen by 1.8% in the fourth quarter. Banque Cantonale Vaudoise now owns 16,363 shares of the company’s stock worth $747,000 after purchasing an additional 290 shares in the last quarter. Commerce Bank raised its holdings in Qiagen by 4.9% in the fourth quarter. Commerce Bank now owns 6,725 shares of the company’s stock worth $302,000 after purchasing an additional 314 shares in the last quarter. Truist Financial Corp raised its holdings in Qiagen by 4.1% in the fourth quarter. Truist Financial Corp now owns 8,421 shares of the company’s stock worth $379,000 after purchasing an additional 331 shares in the last quarter. Finally, Private Advisor Group LLC raised its holdings in Qiagen by 7.1% in the third quarter. Private Advisor Group LLC now owns 5,730 shares of the company’s stock worth $256,000 after purchasing an additional 378 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.